Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 5Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Liposarcoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid and Hematological TP53wt Tumors 1Adenocarcinoma 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × siremadlin × Clear all
NCT05155709 2026-05-07

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Novartis

Phase 1 Completed
14 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05599932 2025-07-09

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Novartis

Phase 1 Completed
38 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02143635 2021-05-21

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Novartis

Phase 1 Completed
208 enrolled

Advanced Solid and Hematological TP53wt Tumors

NCT02343172 2020-12-09

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Novartis

Phase 1 Completed
74 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡